Menu
← Oncology Approval Tracker
FDA DECISION ·
Tecentriq + Avastin
atezolizumab + bevacizumab · Genentech
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Patients with unresectable or metastatic hepatocellular carcinoma who had not received systemic therapy.
LAMPGEN ANALYSIS
Why it matters
Established an immunotherapy and antiangiogenic combination as a first-line option.
What research teams should watch
Plan assessment of bleeding risk and varices and capture baseline liver function.
PRIMARY RECORDS